BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Demarest ST, Brooks-kayal A. From molecules to medicines: the dawn of targeted therapies for genetic epilepsies. Nat Rev Neurol 2018;14:735-45. [DOI: 10.1038/s41582-018-0099-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Wong ZW, Engel T. More than a drug target: Purinergic signalling as a source for diagnostic tools in epilepsy. Neuropharmacology 2023;222:109303. [DOI: 10.1016/j.neuropharm.2022.109303] [Reference Citation Analysis]
2 Asconapé JJ. The development of antiseizure medications. Commentary on The development of antiepileptic drugs by J.W.A. Meijer, H. Meinardi, and C.D. Binnie. Discoveries in Pharmacology 2023. [DOI: 10.1016/b978-0-323-85519-8.00006-7] [Reference Citation Analysis]
3 Ma J, Zhang W, Sun Z, Parvez S, Peterson RT, Yeh JJ. Instantaneous visual genotyping and facile site-specific transgenesis via CRISPR-Cas9 and phiC31 integrase.. [DOI: 10.1101/2022.10.30.514454] [Reference Citation Analysis]
4 Demarest S, Marsh R, Treat L, Fisher MP, Dempsey A, Junaid M, Downs J, Leonard H, Benke T, Morris MA. The Lived Experience of Parents' Receiving the Diagnosis of CDKL5 Deficiency Disorder for Their Child. J Child Neurol 2022;:8830738221076285. [PMID: 35196159 DOI: 10.1177/08830738221076285] [Reference Citation Analysis]
5 Robens BK, Mcgraw CM, Poduri A. Zebrafish as a Model of Genetic Epilepsy and Its Co-occurring Neurobehavioral and Neuropsychiatric Features. Encyclopedia of Behavioral Neuroscience, 2nd edition 2022. [DOI: 10.1016/b978-0-12-819641-0.00147-x] [Reference Citation Analysis]
6 Löscher W. Anti-convulsant Agents: Pharmacology and Biochemistry. NeuroPsychopharmacotherapy 2022. [DOI: 10.1007/978-3-030-62059-2_466] [Reference Citation Analysis]
7 Vo AH, Ambady P, Spencer D. The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma. Epilepsy & Behavior Reports 2022. [DOI: 10.1016/j.ebr.2022.100526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Snyder JM, Gibson‐corley KN, Radaelli E. Nervous System. Pathology of Genetically Engineered and Other Mutant Mice 2021. [DOI: 10.1002/9781119624608.ch21] [Reference Citation Analysis]
9 Terai H, Gwedela MNV, Kawakami K, Aizawa H. Electrophysiological and pharmacological characterization of spreading depolarization in the adult zebrafish tectum. J Neurophysiol 2021;126:1934-42. [PMID: 34731067 DOI: 10.1152/jn.00343.2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Löscher W. Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy. Front Pharmacol 2021;12:730257. [PMID: 34776956 DOI: 10.3389/fphar.2021.730257] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
11 Brock DC, Demarest S, Benke TA. Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies. Neurotherapeutics 2021;18:1445-57. [PMID: 34595733 DOI: 10.1007/s13311-021-01123-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wright SK, Rosch RE, Wilson MA, Upadhya MA, Dhangar DR, Clarke-Bland C, Wahid TT, Barman S, Goebels N, Kreye J, Prüss H, Jacobson L, Bassett DS, Vincent A, Greenhill SD, Woodhall GL. Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis. Commun Biol 2021;4:1106. [PMID: 34545200 DOI: 10.1038/s42003-021-02635-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
13 Löscher W, Klein P. New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal? Pharmacol Ther 2021;:107934. [PMID: 34216705 DOI: 10.1016/j.pharmthera.2021.107934] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Löscher W, Klein P. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs 2021;35:935-63. [PMID: 34145528 DOI: 10.1007/s40263-021-00827-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 26.0] [Reference Citation Analysis]
15 Griffin A, Carpenter C, Liu J, Paterno R, Grone B, Hamling K, Moog M, Dinday MT, Figueroa F, Anvar M, Ononuju C, Qu T, Baraban SC. Phenotypic analysis of catastrophic childhood epilepsy genes. Commun Biol 2021;4:680. [PMID: 34083748 DOI: 10.1038/s42003-021-02221-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
16 Kaat AJ, Zelko F, Wilkening G, Berg AT. Evaluation of the Aberrant Behavior Checklist for Developmental and Epileptic Encephalopathies. Epilepsy Behav 2021;119:107958. [PMID: 33892287 DOI: 10.1016/j.yebeh.2021.107958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sun H, Shen XR, Fang ZB, Jiang ZZ, Wei XJ, Wang ZY, Yu XF. Next-Generation Sequencing Technologies and Neurogenetic Diseases. Life (Basel) 2021;11:361. [PMID: 33921670 DOI: 10.3390/life11040361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Li Y, Lv X, Chen H, Zhi Z, Wei Z, Wang B, Zhou L, Li H, Tang W. Peptide Derived from AHNAK Inhibits Cell Migration and Proliferation in Hirschsprung's Disease by Targeting the ERK1/2 Pathway. J Proteome Res 2021;20:2308-18. [PMID: 33853325 DOI: 10.1021/acs.jproteome.0c00811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Griffin A, Carpenter C, Liu J, Paterno R, Grone B, Hamling K, Moog M, Dinday MT, Figueroa F, Anvar M, Ononuju C, Qu T, Baraban SC. Phenotypic analysis of catastrophic childhood epilepsy genes: The Epilepsy Zebrafish Project.. [DOI: 10.1101/2021.02.11.430844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Löscher W. Anticonvulsant Agents: Pharmacology and Biochemistry. NeuroPsychopharmacotherapy 2021. [DOI: 10.1007/978-3-319-56015-1_466-1] [Reference Citation Analysis]
21 Löscher W. Anticonvulsant Agents: Pharmacology and Biochemistry. NeuroPsychopharmacotherapy 2021. [DOI: 10.1007/978-3-319-56015-1_466-2] [Reference Citation Analysis]
22 Löscher W. Models of Seizures and Epilepsy: Important Tools in the Discovery and Evaluation of Novel Epilepsy Therapies. Neuromethods 2021. [DOI: 10.1007/978-1-0716-1254-5_1] [Reference Citation Analysis]
23 Wright SK, Rosch RE, Wilson MA, Upadhya MA, Dhangar DR, Clarke-bland C, Wahid TT, Barman S, Goebels N, Kreye J, Prüss H, Jacobson L, Bassett DS, Vincent A, Greenhill SD, Woodhall GL. In vitro characterisation and neurosteroid treatment of an N-Methyl-D-Aspartate receptor antibody-mediated seizure model.. [DOI: 10.1101/2020.12.22.423962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Welzel L, Bergin DH, Schidlitzki A, Twele F, Johne M, Klein P, Löscher W. Systematic evaluation of rationally chosen multitargeted drug combinations: a combination of low doses of levetiracetam, atorvastatin and ceftriaxone exerts antiepileptogenic effects in a mouse model of acquired epilepsy. Neurobiol Dis 2021;149:105227. [PMID: 33347976 DOI: 10.1016/j.nbd.2020.105227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Löscher W, Potschka H, Sisodiya SM, Vezzani A. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacol Rev 2020;72:606-38. [PMID: 32540959 DOI: 10.1124/pr.120.019539] [Cited by in Crossref: 157] [Cited by in F6Publishing: 171] [Article Influence: 78.5] [Reference Citation Analysis]
26 Hirose S, Tanaka Y, Shibata M, Kimura Y, Ishikawa M, Higurashi N, Yamamoto T, Ichise E, Chiyonobu T, Ishii A. Application of induced pluripotent stem cells in epilepsy. Molecular and Cellular Neuroscience 2020;108:103535. [DOI: 10.1016/j.mcn.2020.103535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
27 Feng Y, Yang H, Yue Y, Tian F. MicroRNAs and target genes in epileptogenesis. Epilepsia 2020;61:2086-96. [PMID: 32944964 DOI: 10.1111/epi.16687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
28 Forero DA. Functional Genomics of Epileptogenesis in Animal Models and Humans. Cell Mol Neurobiol 2021;41:1579-87. [PMID: 32725455 DOI: 10.1007/s10571-020-00927-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Wagnon JL. Promoting CRISPRa for Targeted Treatment of Epilepsy. Epilepsy Curr 2020;20:227-9. [PMID: 34025235 DOI: 10.1177/1535759720935825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Rubbini D, Cornet C, Terriente J, Di Donato V. CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets. SLAS Discov 2020;25:552-67. [PMID: 32462967 DOI: 10.1177/2472555220926920] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
31 Löscher W, Klein P. The feast and famine: Epilepsy treatment and treatment gaps in early 21st century. Neuropharmacology 2020;170:108055. [PMID: 32199986 DOI: 10.1016/j.neuropharm.2020.108055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
32 Cárdenas-Rodríguez N, Carmona-Aparicio L, Pérez-Lozano DL, Ortega-Cuellar D, Gómez-Manzo S, Ignacio-Mejía I. Genetic variations associated with pharmacoresistant epilepsy (Review). Mol Med Rep 2020;21:1685-701. [PMID: 32319641 DOI: 10.3892/mmr.2020.10999] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Yokoi T, Enomoto Y, Tsurusaki Y, Harada N, Saito T, Nagai JI, Naruto T, Kurosawa K. An efficient genetic test flow for multiple congenital anomalies and intellectual disability. Pediatr Int 2020;62:556-61. [PMID: 31955471 DOI: 10.1111/ped.14159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Da Silva RS, Vianna MRMR, Bonan CD. Seizures and epilepsy. Behavioral and Neural Genetics of Zebrafish 2020. [DOI: 10.1016/b978-0-12-817528-6.00024-3] [Reference Citation Analysis]
35 Lauritano A, Moutton S, Longobardi E, Tran Mau-Them F, Laudati G, Nappi P, Soldovieri MV, Ambrosino P, Cataldi M, Jouan T, Lehalle D, Maurey H, Philippe C, Miceli F, Vitobello A, Taglialatela M. A novel homozygous KCNQ3 loss-of-function variant causes non-syndromic intellectual disability and neonatal-onset pharmacodependent epilepsy. Epilepsia Open 2019;4:464-75. [PMID: 31440727 DOI: 10.1002/epi4.12353] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
36 Liu K, Petree C, Requena T, Varshney P, Varshney GK. Expanding the CRISPR Toolbox in Zebrafish for Studying Development and Disease. Front Cell Dev Biol 2019;7:13. [PMID: 30886848 DOI: 10.3389/fcell.2019.00013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 22.3] [Reference Citation Analysis]
37 Angione K, Eschbach K, Smith G, Joshi C, Demarest S. Genetic testing in a cohort of patients with potential epilepsy with myoclonic-atonic seizures. Epilepsy Res 2019;150:70-7. [PMID: 30660939 DOI: 10.1016/j.eplepsyres.2019.01.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]